论文部分内容阅读
目的观察血液透析滤过(HDF)对慢性维持性血液透析(MHD)患者血清β2-微球蛋白(β2-MG)清除效果及透析充分性。方法应用放射免疫法测定20例MHD患者HDF前、后血清中β2-MG水平,并与同批患者行血液透析(HD)时的透析充分性和临床表现进行比较。结果 HDF后血清β2-MG水平明显下降,与HDF前比较差异有统计学意义(P<0.01)。HDF时KT/V值与TACurea优于HD时,而且患者均有良好的透析耐受性。结论 HDF可有效清除血清中β2-MG。HDF的透析充分性和透析耐受性均比HD好。
Objective To observe the clearance and dialysis adequacy of hemodiafiltration (HDF) on serum β2-microglobulin (β2-MG) in patients with chronic maintenance hemodialysis (MHD). Methods Serum levels of β2-MG before and after HDF were measured by radioimmunoassay in 20 patients with MHD and compared with the dialysis adequacy and clinical manifestations in the same batch of patients undergoing hemodialysis (HD). Results Serum β2-MG level decreased significantly after HDF, with significant difference compared with that before HDF (P <0.01). HDT KT / V values and TACurea better than HD, and patients have good dialysis tolerance. Conclusion HDF can effectively remove β2-MG in serum. HDF dialysis adequacy and dialysis tolerance are better than HD.